LONG-TERM SAFETY OF LETROZONE AND GONADOTROPIN STIMULATION FOR FERTILITY PRESERVATION IN XXXX WITH BREAST CANCER.

@entity1 @entity172 @entity0 @entity5345 @entity5
CONTEXT AND OBJECTIVE: There has been increased attention to the issue of fertility preservation (FP). We aimed to investigate the long-term safety of FP via controlled ovarian stimulation with letrozole supplementation (COSTLES) prior to @entity0 treatment. DESIGN, SETTING AND @entity1 : This is a prospective non-randomized controlled study conducted between the years 2002 and 2014. A total of 337 @entity1 diagnosed with stage  <=3 invasive @entity0 were enrolled during a FP consultation before chemotherapy. Of those, 120 elected to undergo COSTLES for FP prior to chemotherapy (FP group). The remaining 217 @entity1 did not undergo any FP procedure and served as controls. MAIN OUTCOME MEASURE: Primary endpoint was @entity5 recurrence defined as the detection of @entity5 (chest wall, regional nodal disease), distant metastases, or contralateral invasive @entity0 . RESULTS: The baseline characteristics at enrollment were similar between FP and control groups except for the less frequent lymph node involvement (P = 0.02) in the former. The mean follow-up after diagnosis was 5.0 years in the FP and 6.9 years in the control group. In the FP group, the hazard ratio for recurrence after ovarian stimulation was 0.77 (95% CI: 0.28, 2.13) and the survival was not compromised compared with controls (P = 0.61). Neither @entity5345 gene mutation status (P = 0.57), nor undergoing FP before or after breast surgery (P = 0.44) affected survival outcomes in FP group. Likewise, none of the @entity5 characteristics including the @entity172 receptor status affected the survival rates following COSTLES. CONCLUSION: COSTLES is unlikely to cause substantially increased recurrence risk in @entity0 during the 5 years after diagnosis.
